Jefferies & Co Initiates Coverage on Lev Pharmaceuticals (LEVP) with a Buy
LEVP Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Jefferies & Co initiates coverage on Lev Pharmaceuticals (OTCBB: LEVP) with a Buy, citing positive growth outlook. Price target $3.
Lev Pharmaceuticals, Inc. is a development- stage biopharmaceutical company. The Company was established to develop and commercialize therapeutic products for the treatment of inflammatory diseases.
Lev Pharmaceuticals, Inc. is a development- stage biopharmaceutical company. The Company was established to develop and commercialize therapeutic products for the treatment of inflammatory diseases.
You May Also Be Interested In
- UPDATE: Capstone Starts Facebook (FB) at Hold as Premium Multiple Not Justified
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
Create E-mail Alert Related Categories
New CoverageRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
